In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 181 to 190 of 424

TitleTypeExpected publication date
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidanceTBC
Insulin efsitora alfa for treating type 2 diabetes ID6499Technology appraisal guidance
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Technology appraisal guidance
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All